Phase 1 Study of CT-95 in Advanced Cancers Associated with Mesothelin Expression

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CT 95 (Primary)
Indications Adenocarcinoma; Cholangiocarcinoma; Lung cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
Focus Adverse reactions
Sponsors Context Therapeutics

09 Apr 2025 According to a Context Therapeutics media release, company announced that the first patient has been dosed in the Phase 1 clinical trial of CT-95.
20 Mar 2025 According to a Context Therapeutics media release, In April 2025, company will present a poster highlighting first dose selection at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025.
20 Mar 2025 According to a Context Therapeutics media release, company anticipates dosing the first patient in Phase 1 clinical trial of CT-95, in Q2 2025. Additionally, company expects to share initial data from the CT-95 Phase 1 trial in mid-2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com